NASDAQ:GILD - Gilead Sciences Stock Price, Price Target & More

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

Gilead Sciences announced a quarterly dividend on Tuesday, May 1st. Stockholders of record on Friday, June 15th will be paid a dividend of $0.57 per share on Thursday, June 28th. This represents a $2.28 dividend on an annualized basis and a dividend yield of 2.95%. The ex-dividend date of this dividend is Thursday, June 14th. View Gilead Sciences' Dividend History.

Gilead Sciences, Inc. (NASDAQ:GILD) issued its quarterly earnings data on Tuesday, May, 1st. The biopharmaceutical company reported $1.48 earnings per share for the quarter, missing the Zacks' consensus estimate of $1.67 by $0.19. The biopharmaceutical company had revenue of $5.09 billion for the quarter, compared to analysts' expectations of $5.40 billion. Gilead Sciences had a return on equity of 45.49% and a net margin of 14.03%. The company's revenue for the quarter was down 21.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.23 earnings per share. View Gilead Sciences' Earnings History.

Gilead Sciences is scheduled to release their next quarterly earnings announcement on Wednesday, July, 25th 2018. View Earnings Estimates for Gilead Sciences.

25 brokerages have issued twelve-month target prices for Gilead Sciences' stock. Their predictions range from $72.00 to $105.00. On average, they anticipate Gilead Sciences' stock price to reach $88.2271 in the next year. This suggests a possible upside of 14.0% from the stock's current price. View Analyst Ratings for Gilead Sciences.

25 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last year. There are currently 9 hold ratings, 15 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."

Gilead Sciences saw a decline in short interest during the month of June. As of June 29th, there was short interest totalling 13,703,362 shares, a decline of 16.0% from the June 15th total of 16,306,232 shares. Based on an average daily trading volume, of 6,622,004 shares, the short-interest ratio is presently 2.1 days. Approximately 1.1% of the shares of the stock are short sold. View Gilead Sciences' Current Options Chain.

Some companies that are related to Gilead Sciences include Amgen (AMGN), Biogen (BIIB), NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), Qiagen (QGEN), AveXis (AVXS), BIO-TECHNE (TECH), Ablynx (ABLYF), China Biologic Products (CBPO), Spark Therapeutics (ONCE), argenx (ARGX), Aerie Pharmaceuticals (AERI) and Crispr Therapeutics (CRSP).

News stories about GILD stock have been trending somewhat positive recently, Accern Sentiment reports. The research group identifies negative and positive news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Gilead Sciences earned a daily sentiment score of 0.11 on Accern's scale. They also assigned press coverage about the biopharmaceutical company an impact score of 45.43 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Gilead Sciences' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Swedbank (0.15%), Confluence Investment Management LLC (0.09%), Retirement Systems of Alabama (0.08%), NN Investment Partners Holdings N.V. (0.07%), Gateway Investment Advisers LLC (0.06%) and Fisher Asset Management LLC (0.04%). Company insiders that own Gilead Sciences stock include Gayle E Wilson, Gregg H Alton, James R Meyers, John C Martin, John F Milligan, John Francis Cogan, John W Madigan, Kevin E Lofton, Paul Rutherford Carter and Robin L Washington. View Institutional Ownership Trends for Gilead Sciences.

GILD stock was sold by a variety of institutional investors in the last quarter, including Sit Investment Associates Inc., ZWJ Investment Counsel Inc., Howard Capital Management Inc., JLB & Associates Inc., Hartford Investment Management Co., Nippon Life Global Investors Americas Inc., Nisa Investment Advisors LLC and Municipal Employees Retirement System of Michigan. Company insiders that have sold Gilead Sciences company stock in the last year include Gayle E Wilson, Gregg H Alton, James R Meyers, John C Martin, John F Milligan, John Francis Cogan and Robin L Washington. View Insider Buying and Selling for Gilead Sciences.

GILD stock was purchased by a variety of institutional investors in the last quarter, including Confluence Investment Management LLC, Cornerstone Wealth Management LLC, Assenagon Asset Management S.A., Addenda Capital Inc., Columbus Macro LLC, State of Alaska Department of Revenue, Fisher Asset Management LLC and Manning & Napier Group LLC. View Insider Buying and Selling for Gilead Sciences.

Shares of GILD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of GILD stock can currently be purchased for approximately $77.37.

Gilead Sciences has a market capitalization of $100.28 billion and generates $26.11 billion in revenue each year. The biopharmaceutical company earns $4.63 billion in net income (profit) each year or $8.56 on an earnings per share basis. Gilead Sciences employs 10,000 workers across the globe.

Gilead Sciences' mailing address is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. The biopharmaceutical company can be reached via phone at 650-574-3000 or via email at [email protected]